Alnylam Pharmaceuticals authorized a $1 billion share repurchase program, according to a November 4 headline. The supplied facts don’t say when purchases may begin, how long the authorization lasts, or how many shares the company plans to buy. ALNY.US’s latest listed close was US$158.82.
Investor takeaway: The reported event is the $1 billion authorization. Its timing, execution and effect on Alnylam’s share count remain unclear.
The authorized repurchase amount is $1 billion
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$21.57B
P/E
8.1x
52W high
$479.79
52W low
$156.00
1W change
-30.69%
Beta
0.44
Analyst Price Targets
Based on 30 analysts covering ALNY · as of Nov 4, 2026
Wall Street analysts forecast ALNY stock price to rise 93.1% over the next 12 months.
Consensus
Buy4.33 / 5.00
Avg. Target
C$302.48
+93.1% Upside
Previously C$314.81 on Nov 2, 2026
Current Price
C$156.66
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
91.7%
Annualized
90-Day Vol
86.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$131.04
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$147.61 | C$107.58 – C$202.53 |
| 60 trading days | C$139.08 | C$88.91 – C$217.55 |
| 90 trading days | C$131.04 | C$75.76 – C$226.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
The headline reports a $1 billion authorization. The supplied facts don’t include a purchase schedule, execution details or an estimate of how many shares the company might buy.
Bull case
The authorization gives Alnylam the option to spend up to $1 billion on share repurchases.
Bear case
The supplied facts don’t say whether or when Alnylam will buy shares, or how purchases could affect its finances or share count.
What happened: Alnylam authorized a $1 billion repurchase program
Alnylam’s November 4 headline reports that the company authorized a $1 billion share repurchase program. The supplied facts don’t say whether purchases have started, whether Alnylam plans to use the full amount, or how it would fund them. They also don’t estimate how many shares the company could repurchase.
An authorization allows a company to buy back shares, but it doesn’t show how much the company will ultimately buy or when. The headline also mentions a change in commercial leadership, but provides no details to assess it.
What the numbers show: shares closed at US$158.82
Alnylam’s latest listed close was US$158.82, up 0.74% for the day. The supplied figures show declines of 30.69% over one week, 26.75% over one month and 59.75% year to date. The close was near the bottom of the stated 52-week range of US$156.00 to US$479.79.
Latest volume was 307,396 shares, compared with a 20-day average of 2,576,136. The supplied volume comparison is 1.27x. These figures don’t explain the trading activity or show that it was linked to the repurchase announcement. See the Alnylam Pharmaceuticals stock page for more company information.
What to watch next: details on timing and execution
Key questions remain: When might Alnylam begin buying shares? How much of the $1 billion authorization will it use, and over what period? The supplied facts don’t answer these questions, so the authorization alone doesn’t show how the program could affect the company’s share count or financial position.
Investors can watch for more information about the repurchase program and the commercial leadership change mentioned in the November 4 headline. The supplied facts don’t say when the company may provide further details. The ALNY stock page lists the quote and other supplied market data.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
